Literature DB >> 16702209

The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression.

Shu-Jen Chen1, Hongyan Ning, Wataru Ishida, Snezna Sodin-Semrl, Shinsuke Takagawa, Yasuji Mori, John Varga.   

Abstract

Transforming growth factor-beta (TGF-beta) stimulates collagen synthesis and accumulation, and aberrant TGF-beta signaling is implicated in pathological organ fibrosis. Regulation of type I procollagen gene (COL1A2) transcription by TGF-beta involves the canonical Smad signaling pathway as well as additional protein and lipid kinases, coactivators, and DNA-binding transcription factors that constitute alternate non-Smad pathways. By using Affymetrix microarrays to detect cellular genes whose expression is regulated by Smad3, we identified early growth response factor-1 (EGR-1) as a novel Smad3-inducible gene. Previous studies implicated Egr-1 in cell growth, differentiation, and survival. We found that TGF-beta induced rapid and transient accumulation of Egr-1 protein and mRNA in human skin fibroblasts. In transient transfection assays, TGF-beta stimulated the activity of the Egr-1 gene promoter, as well as that of a minimal Egr-1-responsive reporter construct. Furthermore, TGF-beta enhanced endogenous Egr-1 interaction with a consensus Egr-1-binding site element and with GC-rich DNA sequences of the human COL1A2 promoter in vitro and in vivo. Forced expression of Egr-1 by itself caused dose-dependent up-regulation of COL1A2 promoter activity and further enhanced the stimulation induced by TGF-beta. In contrast, the TGF-beta response was abrogated when the Egr-1-binding sites of the COL1A2 promoter were mutated or deleted. Furthermore, Egr-1-deficient embryonic mouse fibroblasts showed attenuated TGF-beta responses despite intact Smad activation, and forced expression of ectopic EGR-1 in these cells could restore COL1A2 stimulation in a dose-dependent manner. Taken together, these findings identify Egr-1 as a novel intracellular TGF-beta target that is necessary for maximal stimulation of collagen gene expression in fibroblasts. The results therefore implicate Egr-1 in the profibrotic responses elicited by TGF-beta and suggest that Egr-1 may play a new and important role in the pathogenesis of fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702209     DOI: 10.1074/jbc.M603270200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  83 in total

1.  The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Authors:  Feng Fang; Kohtaro Ooka; Swati Bhattacharyya; Swati Bhattachyya; Jun Wei; Minghua Wu; Pan Du; Simon Lin; Francesco Del Galdo; Carol A Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy.

Authors:  Swati Bhattacharyya; Minghua Wu; Feng Fang; Warren Tourtellotte; Carol Feghali-Bostwick; John Varga
Journal:  Matrix Biol       Date:  2011-04-13       Impact factor: 11.583

Review 3.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

4.  HIF-1α deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency.

Authors:  Jinwei Du; Yu Chen; Qiang Li; Xiangzi Han; Cindy Cheng; Zhengqi Wang; David Danielpour; Sally L Dunwoodie; Kevin D Bunting; Yu-Chung Yang
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

5.  The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.

Authors:  Vladimír Cermák; Jan Kosla; Jirí Plachý; Katerina Trejbalová; Jirí Hejnar; Michal Dvorák
Journal:  Cell Mol Life Sci       Date:  2010-05-28       Impact factor: 9.261

6.  MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.

Authors:  Lisa Koetz-Ploch; Douglas Hanniford; Igor Dolgalev; Elena Sokolova; Judy Zhong; Marta Díaz-Martínez; Emily Bernstein; Farbod Darvishian; Keith T Flaherty; Paul B Chapman; Hussein Tawbi; Eva Hernando
Journal:  Pigment Cell Melanoma Res       Date:  2017-04-19       Impact factor: 4.693

7.  Mislocalized scaffolding by the Na-H exchanger NHE1 dominantly inhibits fibronectin production and TGF-beta activation.

Authors:  Anastasios Karydis; Maite Jimenez-Vidal; Sheryl P Denker; Diane L Barber
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

Review 8.  TGF-β1 Signaling and Tissue Fibrosis.

Authors:  Kevin K Kim; Dean Sheppard; Harold A Chapman
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

9.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

10.  Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness.

Authors:  Yasuji Mori; Monique Hinchcliff; Minghua Wu; Matthew Warner-Blankenship; Karen M Lyons; John Varga
Journal:  Exp Cell Res       Date:  2007-12-23       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.